Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iAnthus Capital HoldingsFRA:2IA Receivables Turnover is 5.12 as of Mar. 2026. The stock has 4 warning signs investors should review. Among 950 Drug Manufacturers companies, iAnthus Capital Holdings ranks better than 95.26% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. iAnthus Capital Holdings's Revenue for the
three
months ended in Mar. 2026 was €29.0 Mil. iAnthus Capital Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was €5.7 Mil.
Hence, iAnthus Capital Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.12.
iAnthus Capital Holdings (FRA:2IA) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
iAnthus Capital Holdings Receivables Turnover Related Terms
iAnthus Capital Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for iAnthus Capital Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings Receivables Turnover Chart
FRA:2IA vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iAnthus Capital Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iAnthus Capital Holdings Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iAnthus Capital Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where iAnthus Capital Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings (FRA:2IA) has a Receivables Turnover of 5.12 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iAnthus Capital Holdings and its competitors. According to the industry distribution chart, iAnthus Capital Holdings ranks #45 out of 950 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is iAnthus Capital Holdings' Receivables Turnover too high?
iAnthus Capital Holdings' current Receivables Turnover is 5.12. The Drug Manufacturers industry median Receivables Turnover is 5.07. iAnthus Capital Holdings' value of 5.12 is 1% above this industry median. Based on the distribution chart, iAnthus Capital Holdings ranks #45 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does iAnthus Capital Holdings' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iAnthus Capital Holdings ranks #45 out of 950 companies for Receivables Turnover. This places iAnthus Capital Holdings in the top 5% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. iAnthus Capital Holdings' value of 5.12 is 1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iAnthus Capital Holdings's current Receivables Turnover of 5.12 is 1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on iAnthus Capital Holdings and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iAnthus Capital Holdings's current Receivables Turnover is 5.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iAnthus Capital Holdings stock overvalued right now?
iAnthus Capital Holdings (FRA:2IA) has a current Receivables Turnover of 5.12. The current Receivables Turnover is 5.12 and 1% above the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For iAnthus Capital Holdings (FRA:2IA), the current Receivables Turnover is 5.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iAnthus Capital Holdings Inc is a vertically-integrated, multi-state owner and operator of licensed cannabis cultivation, processing, and dispensary facilities and a developer, producer, and distributor of branded cannabis products in the United States. Its Cannabis product offerings include flower and trim, products containing cannabis flower and trim (such as packaged flower and pre-rolls), cannabis infused products (such as topical creams and edibles), and products containing cannabis extracts (such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures). The company's reportable operating segments are the Eastern Region, which generates the maximum revenue, and the Western Region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2IA has been successfully added to your 
